May 11, 2017
2 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: Biologics show efficacy, safety in patients with giant cell arteritis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
DESTIN, Fla. — At the Congress of Clinical Rheumatology Annual Meeting, Robert F. Spiera, MD, from Hospital for Special Surgery, spoke about the need to find a steroid-sparing agent for patients with giant cell arteritis (GCA) and how biologics have shown efficacy and safety in some small studies for these patients.
Spiera mentioned abatacept, which demonstrated efficacy in a placebo-controlled trial of 50 patients, and tocilizumab, which showed a steroid-sparing benefit and maintenance of relapse-free survival in another published study.